Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 22, 2026, 4:15 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 241–264 of 2,297 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Induction Phase Clear all
Completed Phase 2 Interventional Results available

Sunitinib Maintenance Therapy After Induction Platinum-Based Chemotherapy in Patients With ES-SCLC

NCT00616109
View directory record Official record
Conditions
Extensive-Stage Small Cell Lung Cancer
Interventions
sunitinib
Drug
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Apr 21, 2014 · Synced Oct 22, 2026, 4:15 PM EDT
Terminated Phase 3 Interventional Results available

HMPL-004 Maintenance Treatment in Subjects With Mild to Moderate Ulcerative Colitis

NCT01882764
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
HMPL-004, Placebo
Drug
Lead sponsor
Hutchison Medipharma Limited
Industry
Eligibility
18 Years and older
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Agawam, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 13, 2020 · Synced Oct 22, 2026, 4:15 PM EDT
Terminated Phase 3 Interventional

Efficacy (Induction of Response/Remission) and Safety Study in Patients With Moderate to Severe Crohn's Disease

NCT00295165
View directory record Official record
Conditions
Crohn Disease
Interventions
Sargramostim (Leukine), Placebo
Drug
Lead sponsor
Genzyme, a Sanofi Company
Industry
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006
U.S. locations
47
States / cities
Huntsville, Alabama • Orange, California • San Francisco, California + 43 more
Source: ClinicalTrials.gov public record
Updated Dec 4, 2013 · Synced Oct 22, 2026, 4:15 PM EDT
Terminated Phase 1 Interventional

Intrathecal Gemcitabine to Treat Neoplastic Meningitis, IT Gemcitabine

NCT00074607
View directory record Official record
Conditions
Meningitis, Neoplasms
Interventions
Gemcitabine
Drug
Lead sponsor
Baylor College of Medicine
Other
Eligibility
3 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2007
U.S. locations
5
States / cities
Bethesda, Maryland • Pittsburgh, Pennsylvania • Houston, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Nov 12, 2012 · Synced Oct 22, 2026, 4:15 PM EDT
Completed Phase 1 Interventional

Dasatinib, Paclitaxel, and Carboplatin in Treating Patients With Stage III-IV or Recurrent Endometrial Cancer

NCT01440998
View directory record Official record
Conditions
Endometrial Adenocarcinoma, Endometrial Clear Cell Adenocarcinoma, Endometrial Mucinous Adenocarcinoma, Endometrial Serous Adenocarcinoma, Endometrial Squamous Cell Carcinoma, Endometrial Transitional Cell Carcinoma, Endometrial Undifferentiated Carcinoma, Endometrioid Adenocarcinoma, Recurrent Uterine Corpus Carcinoma, Stage III Uterine Corpus Cancer AJCC v7, Stage IIIA Uterine Corpus Cancer AJCC v7, Stage IIIB Uterine Corpus Cancer AJCC v7, Stage IIIC Uterine Corpus Cancer AJCC v7, Stage IV Uterine Corpus Cancer AJCC v7, Stage IVA Uterine Corpus Cancer AJCC v7, Stage IVB Uterine Corpus Cancer AJCC v7
Interventions
Carboplatin, Dasatinib, Laboratory Biomarker Analysis, Paclitaxel
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Female only
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 5, 2018 · Synced Oct 22, 2026, 4:15 PM EDT
Completed Phase 1 Interventional

Calcium and Magnesium Infusion for the Prevention of Taxane Induced Neuropathy

NCT01682499
View directory record Official record
Conditions
Paclitaxel-induced Neuropathy
Interventions
calcium gluconate and magnesium sulfate
Drug
Lead sponsor
Beth Israel Medical Center
Other
Eligibility
21 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
3
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 25, 2014 · Synced Oct 22, 2026, 4:15 PM EDT
Completed Phase 1Phase 2 Interventional

MRI Sarcoma Non Invasive Thermometry

NCT00093509
View directory record Official record
Conditions
Sarcoma
Interventions
doxorubicin hydrochloride, ifosfamide and mesna, hyperthermia treatment with an MRI Compatible Radiofrequency Extremity Hyperthermia Applicator, radiation therapy
Drug · Procedure · Radiation
Lead sponsor
Mark Dewhirst
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2009
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 1, 2014 · Synced Oct 22, 2026, 4:15 PM EDT
Completed Phase 3 Interventional Results available

A Study Evaluating The Efficacy And Safety Of CP-690,550 In Patients With Moderate To Severe Ulcerative Colitis

NCT01465763
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
tofacitinib, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
614 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
71
States / cities
Mobile, Alabama • La Jolla, California • Los Angeles, California + 29 more
Source: ClinicalTrials.gov public record
Updated Jun 7, 2016 · Synced Oct 22, 2026, 4:15 PM EDT
Not listed Phase 4 Interventional

Macugen for Proliferative Diabetic Retinopathy Study With Extended Dosing (M-PDRS ED)

NCT01486771
View directory record Official record
Conditions
Proliferative Diabetic Retinopathy
Interventions
Macugen ® (pegaptanib sodium)
Drug
Lead sponsor
Valley Retina Institute
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2014
U.S. locations
1
States / cities
McAllen, Texas
Source: ClinicalTrials.gov public record
Updated Dec 6, 2011 · Synced Oct 22, 2026, 4:15 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional

Modern Immunotherapy in BCG-Unresponsive, BCG-Relapsing and High Risk BCG-Naive Non-Muscle Invasive Urothelial Carcinoma of the Bladder

NCT03317158
View directory record Official record
Conditions
Urothelial Carcinoma, Bladder Cancer
Interventions
Durvalumab (Cohort 1-3), External Beam Radiotherapy (EBRT), Bacillus Calmette-Guérin (BCG), Gemcitabine, Docetaxel, Tremelimumab, Durvalumab (Cohort 4/5), To be determined, Intravesical NAI (Cohorts 6-7), Subcutaneous NAI (Cohort 8)
Drug · Radiation · Biological + 1 more
Lead sponsor
Noah Hahn, M.D.
Other
Eligibility
18 Years and older
Enrollment
186 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2029
U.S. locations
9
States / cities
Phoenix, Arizona • Indianapolis, Indiana • Iowa City, Iowa + 6 more
Source: ClinicalTrials.gov public record
Updated Jul 15, 2026 · Synced Oct 22, 2026, 4:15 PM EDT
Active, not recruiting Phase 2 Interventional

Blinatumomab and Tyrosine Kinase Inhibitor Therapy in People With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia

NCT04329325
View directory record Official record
Conditions
Acute Lymphoblastic Leukemia, Philadelphia Chromosome-Positive
Interventions
Blinatumomab, dasatinib, dexamethasone, methotrexate
Biological · Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
2
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 7, 2026 · Synced Oct 22, 2026, 4:15 PM EDT
Terminated Phase 3 Interventional Results available

Efficacy and Safety Study of Ontamalimab as Induction Therapy in Participants With Moderate to Severe Crohn's Disease (CARMEN CD 305)

NCT03559517
View directory record Official record
Conditions
Crohn's Disease
Interventions
Ontamalimab, Placebo
Biological · Other
Lead sponsor
Shire
Industry
Eligibility
16 Years to 80 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
25
States / cities
Tucson, Arizona • Little Rock, Arkansas • Lancaster, California + 20 more
Source: ClinicalTrials.gov public record
Updated Apr 29, 2021 · Synced Oct 22, 2026, 4:15 PM EDT
Recruiting Phase 1 Interventional

SL-401 in Combination With Azacitidine or Azacitidine/Venetoclax in Acute Myeloid Leukemia (AML), High-Risk Myelodysplastic Syndrome (MDS) or Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)

NCT03113643
View directory record Official record
Conditions
Acute Myeloid Leukemia, Myelodysplastic Syndrome, Blastic Plasmacytoid Dendritic Cell Neoplasm
Interventions
Azacitidine, SL-401, Venetoclax
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2027
U.S. locations
3
States / cities
Duarte, California • Boston, Massachusetts • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 17, 2026 · Synced Oct 22, 2026, 4:15 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety Study to Evaluate Vadadustat for the Correction or Maintenance Treatment of Anemia in Participants With Incident Dialysis-dependent Chronic Kidney Disease (DD-CKD)

NCT02865850
View directory record Official record
Conditions
Anemia, Dialysis-Dependent Chronic Kidney Disease
Interventions
Vadadustat, Darbepoetin alfa
Drug
Lead sponsor
Akebia Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
369 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
54
States / cities
Huntsville, Alabama • Mesa, Arizona • Anaheim, California + 45 more
Source: ClinicalTrials.gov public record
Updated Jul 18, 2022 · Synced Oct 22, 2026, 4:15 PM EDT
Completed Phase 3 Interventional Results available

Zevalin-beam for Aggressive Lymphoma

NCT00491491
View directory record Official record
Conditions
Non-Hodgkin's Lymphoma
Interventions
ibritumomab tiuxetan, BEAM chemotherapy and autologous stem-cell transplantation
Drug · Procedure
Lead sponsor
Sheba Medical Center
Government
Eligibility
18 Years to 70 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2015
U.S. locations
6
States / cities
Scottsdale, Arizona • Duarte, California • Los Angeles, California + 3 more
Source: ClinicalTrials.gov public record
Updated Aug 31, 2020 · Synced Oct 22, 2026, 4:15 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

The Brain on Whole Body Hyperthermia: A Neuroimaging Study

NCT02062840
View directory record Official record
Conditions
Major Depression
Interventions
High intensity whole-body infrared heating, Low intensity whole-body infrared heating, Functional Magnetic Resonance Imaging (fMRI) and electrocardiogram (EKG), Questionnaires
Device · Other
Lead sponsor
University of Arizona
Other
Eligibility
18 Years to 30 Years
Enrollment
23 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
1
States / cities
Tucson, Arizona
Source: ClinicalTrials.gov public record
Updated Aug 10, 2015 · Synced Oct 22, 2026, 4:15 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Combination Chemotherapy, Bev, RT, and Erlotinib in Treating Patients With Stage III Non-Small Cell Lung Cancer

NCT00280150
View directory record Official record
Conditions
Lung Cancer
Interventions
bevacizumab, carboplatin, erlotinib hydrochloride, paclitaxel, 3-dimensional conformal radiation therapy
Biological · Drug · Radiation
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
18 Years to 120 Years
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2013
U.S. locations
3
States / cities
Chapel Hill, North Carolina • Concord, North Carolina • Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 19, 2017 · Synced Oct 22, 2026, 4:15 PM EDT
Terminated Phase 2 Interventional Results available

A Study to Investigate the Use of Benralizumab in Patients With Chronic Spontaneous Urticaria Who Are Symptomatic Despite the Use of Antihistamines (ARROYO)

NCT04612725
View directory record Official record
Conditions
Chronic Spontaneous Urticaria
Interventions
Benralizumab, Placebo and Benralizumab
Biological
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
159 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
12
States / cities
Scottsdale, Arizona • Los Angeles, California • Mission Viejo, California + 8 more
Source: ClinicalTrials.gov public record
Updated Mar 13, 2024 · Synced Oct 22, 2026, 4:15 PM EDT
Active, not recruiting Phase 2 Interventional

A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Ulcerative Colitis

NCT06254950
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
TAK-279, Placebo
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 75 Years
Enrollment
213 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
16
States / cities
Los Angeles, California • Murrieta, California • Clearwater, Florida + 13 more
Source: ClinicalTrials.gov public record
Updated Aug 17, 2026 · Synced Oct 22, 2026, 4:15 PM EDT
Completed Phase 3 Interventional Results available

Daunorubicin & Cytarabine +/- Zosuquidar inTreating Older Patients With Newly Diagnosed Acute Myeloid Leukemia or Refractory Anemia

NCT00046930
View directory record Official record
Conditions
Leukemia, Myelodysplastic Syndromes
Interventions
filgrastim, sargramostim, cytarabine, daunorubicin hydrochloride, zosuquidar trihydrochloride, Placebo
Biological · Drug
Lead sponsor
Eastern Cooperative Oncology Group
Network
Eligibility
60 Years and older
Enrollment
449 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2002
U.S. locations
91
States / cities
Scottsdale, Arizona • Aurora, Colorado • Boulder, Colorado + 67 more
Source: ClinicalTrials.gov public record
Updated Jul 5, 2023 · Synced Oct 22, 2026, 4:15 PM EDT
Terminated Phase 2 Interventional Results available

Phase 2A Open Label Safety Study of Fovista® (Anti-PDGF BB) Regimen Administered in Combination With Anti-VEGF Therapy to Study Sub-Retinal Fibrosis in Neovascular AMD

NCT02214628
View directory record Official record
Conditions
Age-related Macular Degeneration
Interventions
Fovista® (anti-PDGF BB) plus anti-VEGF
Drug
Lead sponsor
Ophthotech Corporation
Industry
Eligibility
50 Years and older
Enrollment
101 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
13
States / cities
Phoenix, Arizona • Beverly Hills, California • Sacramento, California + 9 more
Source: ClinicalTrials.gov public record
Updated Feb 23, 2024 · Synced Oct 22, 2026, 4:15 PM EDT
Terminated Phase 2 Interventional Results available

Study of Pembrolizumab and Concurrent Radiation in Patients With Previously Treated Carcinoma of Unknown Primary

NCT03396471
View directory record Official record
Conditions
Carcinoma, Unspecified Site
Interventions
Pembrolizumab, External Beam Radiation Therapy
Drug · Radiation
Lead sponsor
Hoosier Cancer Research Network
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
2
States / cities
Rochester, Minnesota • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 18, 2024 · Synced Oct 22, 2026, 4:15 PM EDT
Completed Phase 2 Interventional Results available

Perioperative Therapy for Resectable Pancreatic Cancer

NCT00609336
View directory record Official record
Conditions
Adenocarcinoma of the Pancreas, Stage IA Pancreatic Cancer, Stage IB Pancreatic Cancer, Stage IIA Pancreatic Cancer, Stage IIB Pancreatic Cancer
Interventions
gemcitabine hydrochloride, docetaxel, capecitabine, intensity-modulated radiation therapy, oxaliplatin, pancreatic surgical procedure, therapeutic conventional surgery, laboratory biomarker analysis
Drug · Radiation · Procedure + 1 more
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2016
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jul 13, 2017 · Synced Oct 22, 2026, 4:15 PM EDT
Completed Phase 2 Interventional

Radiation Therapy and Combination Chemotherapy in Treating Patients With Stage III or Stage IV Head and Neck Cancer

NCT00002774
View directory record Official record
Conditions
Squamous Neck Carcinoma of the Head and Neck Cancer (SCCHN)
Interventions
Tirapazamine, Cisplatin, 5-fluorouracil, Radiotherapy (RT)
Drug · Radiation
Lead sponsor
Stanford University
Other
Eligibility
17 Years and older
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1996 – 2005
U.S. locations
2
States / cities
Palo Alto, California • Stanford, California
Source: ClinicalTrials.gov public record
Updated Jun 20, 2014 · Synced Oct 22, 2026, 4:15 PM EDT